Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
== Pathophysiology == The primary characteristic of MASLD is the accumulation of lipids in the liver, largely in the form of triglycerides. However, the mechanisms by which triglycerides accumulate and the reasons that accumulation can lead to liver dysfunction are complex and incompletely understood. MASLD can include steatosis along with varied signs of liver injury: either lobular or portal inflammation (a form of liver injury) or ballooning degeneration. Similarly, MASH can include histological features such as portal inflammation, polymorphonuclear cell infiltrates, Mallory bodies, apoptotic bodies, clear vacuolated nuclei, microvesicular steatosis, megamitochondria, and perisinusoidal fibrosis. Hepatocyte death via apoptosis or necroptosis is increased in MASH compared with simple steatosis, and inflammation is a hallmark of MASH. The degree of inflammation can be correlated to the number of inflammatory foci. Various definitions exist for an inflammatory focus, but one defines it as the presence of more than four mononuclear cells in proximity within the hepatic parenchyma. One debated mechanism proposes that hepatic steatosis progresses to steatosis with inflammation following some further injury, or second hit. Oxidative stress, hormonal imbalances, and mitochondrial abnormalities are potential causes of this "second hit" phenomenon. A further nutrigenomics model named multiple hit extends the second hit model, suggesting that multiple disease biomarkers and factors such as genes and nutrition influence MASLD and MASH progression.
=== Number of vibrational modes === In order for a vibrational mode in a sample to be "IR active", it must be associated with changes in the molecular dipole moment. A permanent dipole is not necessary, as the rule requires only a change in dipole moment. A molecule can vibrate in many ways, and each way is called a vibrational mode. For molecules with N number of atoms, geometrically linear molecules have 3N – 5 degrees of vibrational modes, whereas nonlinear molecules have 3N – 6 degrees of vibrational modes (also called vibrational degrees of freedom). As examples linear carbon dioxide (CO2) has 3 × 3 – 5 = 4, while non-linear water (H2O), has only 3 × 3 – 6 = 3.
In 2015, Schumer was named one of Time magazine's 100 most influential people. Schumer was named to Barbara Walters' 10 Most Fascinating People for 2015. Schumer has received praise for addressing various social issues through comedy. Throughout 2015, several of Schumer's skits in Inside Amy Schumer went viral online, sparking editorials regarding sex, feminism, and rape culture. In June 2015, Monica Heisey of The Guardian criticized her for "a shockingly large blind spot around race". Schumer responded on Twitter, stating "I go in and out of playing an irreverent idiot. That includes making dumb jokes involving race ... You can call it a 'blind spot for racism' or 'lazy,' but you are wrong. It is a joke ... I am not racist." Schumer was again criticized in July 2020 by Kyndall Cunningham of The Daily Beast for her earlier work, which included "objectifying black men" and calling Latina women "crazy". Cunningham described her "sudden" decision to support the Black Lives Matter movement as "befuddling and laughable". After a fatal shooting took place at a showing of Trainwreck in Louisiana, Schumer advocated for stricter gun control laws and increased mental health funding. After her 2018 wedding, Schumer asked fans to donate to Everytown for Gun Safety instead of giving wedding gifts. In November 2015, Schumer posed nude for a photo by photographer Annie Leibovitz for the 2016 edition of the Pirelli Calendar. Schumer tweeted the photo, writing "Beautiful, gross, strong, thin, fat, pretty, ugly, sexy, disgusting, flawless, woman.
The skeletons of arthropods, including insects, crustaceans, and arachnids, are cuticle exoskeletons. They are composed of chitin secreted by the epidermis. The cuticle covers the animal's body and lines several internal organs, including parts of the digestive system. Arthropods molt as they grow through a process of ecdysis, developing a new exoskeleton, digesting part of the previous skeleton, and leaving the remainder behind. An arthropod's skeleton serves many functions, working as an integument to provide a barrier and support the body, providing appendages for movement and defense, and assisting in sensory perception. Some arthropods, such as crustaceans, absorb biominerals like calcium carbonate from the environment to strengthen the cuticle.
Sources: en.wikipedia.org
== Trivial names of some resorcinolic lipids == olivetol persoonol grevillol ardisinol I ardisinol II adipostatin A adipostatin B bilobol hexylresorcinol hydrobilobol cardol rucinol irisresorcinol panosialin stemphol R-leprosol α-leprosol merulinic acid xenognosin
Pulp degeneration Increasing age Orthodontic treatment Traumatic occlusion Dental caries Pulp stones usually consist of circular layers of mineralised tissues. These layers are made up of blood clots, dead cells and collagen fibres. Occasionally, pulp stones appear surrounded by odontoblast-like cells that contain tubules. Pulp stones can reach as high as 50% in surveyed samples. Pulp stones are estimated to typically range from 8–9%. Pulpal calcifications are more common in females and more frequent in maxillary teeth compared to mandibular teeth. The reason is uncertain. They are more common in molar teeth, especially first molars compared to second molars and premolars. A review suggested this was because the first molars are the first teeth to be located in the mandible (lower jaw) and have longer exposure to degenerative changes. They also have a larger blood supply. In general, pulp stones do not require treatment. Depending on the stones' size and location, they may interfere with endodontic treatment and should be removed.
=== Third-generation boron delivery agents === As alternatives to BSH and BPA, "third-generation boron delivery agents" are marked by inclusion of a specific chemical tumor-targeting moiety, often borrowed from those established in chemotherapy, linked to a boron-carrying compound. These targeted drug delivery systems are designed to bind the delivery agent to chemical sites found in tumor cells, rather than relying on secondary properties such as hydrophilicity; the use of BPA to target melanomas was an early example. Third-generation agents are also multifunctional, with cancer-targeting and imaging capabilities. Examples of compounds derivativized for BNCT include "peptides, proteins, antibodies, nucleosides, sugars, porphyrins, liposomes and nanoparticles." Nanoparticles conjugated with boron-containing compounds can target tumor-specific receptors and accumulate in cancer cells. One aspect that is being taken advantage of is the increased uptake of glucose in tumors compared to normal cells. This increase in glucose is due to the upregulated anaerobic glycolysis required in tumor cells, allowing for glucose transporters (GLUT) to be targeted by boron compounds to increase selectivity of tumor cells. Monoclonal antibodies are also being engineered to take advantage of antigens that are overexpressed in tumor cells to increase the tumor-normal tissue ratio. The use of engineered antibodies can allow specificity to patients based on their unique antigenic profiles.
Sources: en.wikipedia.org
Li2CO3 + CO2 + H2O ⇌ 2 LiHCO3 The extraction of lithium carbonate at high pressures of CO2 and its precipitation upon depressurizing is the basis of the Quebec process. Lithium carbonate can also be purified by exploiting its diminished solubility in hot water. Thus, heating a saturated aqueous solution causes crystallization of Li2CO3. Lithium carbonate, and other carbonates of group 1, do not decarboxylate readily. Li2CO3 decomposes at temperatures around 1300 °C.
The Raleigh area has hosted the Professional Golfers' Association (PGA) Nationwide Tour Rex Hospital Open since 1994, with the current location of play at Raleigh's Country Club at Wakefield Plantation. Nearby Prestonwood Country Club hosts the PGA SAS Championship every fall.
=== Criteria === There are three sets of criteria for the clinical diagnoses of the spectrum of Alzheimer's disease: the 2013 fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); the National Institute on Aging-Alzheimer's Association (NIA-AA) definition as revised in 2011; and the International Working Group criteria as revised in 2010. Eight intellectual domains are most commonly impaired in AD—memory, language, perceptual skills, attention, motor skills, orientation, problem solving and executive functional abilities, as listed in the fourth text revision of the DSM (DSM-IV-TR). The DSM-5 defines criteria for probable or possible AD for both major and mild neurocognitive disorders. Major or mild neurocognitive disorder must be present along with at least one cognitive deficit for a diagnosis of either probable or possible AD. For major neurocognitive disorder due to AD, probable Alzheimer's disease can be diagnosed if the individual has genetic evidence of AD or if two or more acquired cognitive deficits, and a functional disability that is not from another disorder, are present. Otherwise, possible AD can be diagnosed as the diagnosis follows an atypical route. For mild neurocognitive disorder due to AD, probable Alzheimer's disease can be diagnosed if there is genetic evidence, whereas possible AD can be met if all of the following are present: no genetic evidence, decline in both learning and memory, two or more cognitive deficits, and a functional disability not from another disorder.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.